Skip to main content
Article thumbnail
Location of Repository

Wharton’s jelly or bone marrow mesenchymal stromal cells improve cardiac function following myocardial infarction for more than 32 weeks in a rat model: a preliminary report

By Yelica López, Barbara Lutjemeier, Kiran Seshareddy, Elizabeth M. Trevino, Karen S. Hageman, Timothy I. Musch, Michele Borgarelli and Mark L. Weiss


The therapeutic effect of mesenchymal stromal cells (MSCs) following myocardial infarction (MI) is small. This may be due to differences in cellular sources and donor age, route of administration, in vitro cellular manipulations and the short time course of follow up in many animal studies. Here, we compared MSCs from two different sources (adult bone marrow or Wharton’s jelly from umbilical cord) for their long-term therapeutic effect following MI in a rat model to evaluate the effect of donor age. MSCs (or control infusions) were given intravenously 24-48 hr after myocardial ischemia (MI) induced by coronary artery ligation. Cardiac function was assessed by ultrasound at time points starting from before MSC infusion through 68 weeks after MI. A significant improvement in ejection fraction was seen in animals that received MSCs in time points 25 to 31 wks after treatment (p <0.01). These results support previous work that show that MSCs can cause improvement in cardiac function and extend that work by showing that the beneficial effects are durable. To investigate MSCs’ cardiac differentiation potential, Wharton’s jelly MSCs were co-cultured with fetal or adult bone-derived marrow MSCs. When Wharton’s jelly MSCs were co-cultured with fetal MSCs, and not with adult MSCs, myotube structures were observed in two-three days and spontaneous contractions (beating) cells were observed in fiveseven days. The beating structures formed a functional syncytium indicated by coordinated contractions (beating) of independent nodes. Taken together, these results suggest that MSCs given 24-48 hr after MI have a significant and durable beneficial effect more than 25 weeks after MI and that MSC treatment can home to damaged tissue and improve heart function after intravenous infusion 24-48 hrs after MI, and that WJCs may be a useful source for off-the-shelf cellular therapy for MI

Topics: Bone marrow, Cardiomyocyte differentiation, Cellular therapy, Mesenchymal stromal cells, Myocardial ischemia, Preclinical testing, Rat, Echocardiography, Wharton’s jelly
Year: 2013
OAI identifier:

Suggested articles


  1. (2013). 5-Azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and 58
  2. (2011). Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-alpha stimulated gene/protein 6. Stem Cells
  3. (2000). Adipose-derived stromal cells--their utility and potential in bone formation.
  4. (1989). Age dependent in vitro stromal growth. Bone Marrow Transplant
  5. (2011). Age-related changes in rat bone-marrow mesenchymal stem cell plasticity.
  6. (2006). Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet
  7. (2004). Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept
  8. (2008). BMP-2 and FGF-2 synergistically facilitate a doption of a cardiac phenotype in somatic bone marrow c-kit+/Sca-1+ stem cells. Clin Transl Sci
  9. (2007). Bone marrow cells adopt the cardiomyogenic fate in vivo.
  10. (2002). Bone marrow-derived regenerated cardiomyocytes (CMG Cells) express functional adrenergic and muscarinic receptors. Circulation
  11. (2008). Bone marrow-derived side population cells are capable of functional cardiomyogenic differentiation. Mol Cells
  12. (2004). Both cell fusion and transdifferentiation account for the transformation of human peripheral blood CD34-positive cells into cardiomyocytes in vivo. Circulation
  13. (2009). Cardiac differentiation is driven by NKX2.5 and GATA4 nuclear translocation in tissuespecific mesenchymal stem cells. Stem Cells Dev
  14. (1999). Cardiomyocytes can be generated from marrow stromal cells in vitro.
  15. (2010). Cell therapy for heart failure: the need for a new therapeutic strategy. Expert Rev Cardiovasc Ther
  16. (2010). Cell therapy for the treatment of coronary heart disease: a critical appraisal. Nat Rev Cardiol
  17. (2002). Chondrogenic potential of adipose tissue-derived stromal cells in vitro and in vivo.
  18. (2005). Clinical trials using autologous bone marrow and peripheral blood-derived progenitor cells in patients with acute myocardial infarction. Folia Histochem Cytobiol
  19. (2008). Comparison of human placenta- and bone marrow-derived multipotent mesenchymal stem cells. Stem Cells Dev
  20. (2007). Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells
  21. (2007). Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells
  22. (2005). Contribution of human bone marrow stem cells to individual skeletal myotubes followed by myogenic gene activation. Exp Cell Res
  23. (2008). Difluoromethylornithine stimulates early cardiac commitment of mesenchymal stem cells in a model of mixed culture with cardiomyocytes.
  24. (2011). Effect of 5-azacytidine: evidence for alteration of the multipotent ability of mesenchymal stem cells. Stem Cells Dev
  25. (2012). Effect of cyclic strain on cardiomyogenic differentiation of rat bone marrow derived mesenchymal stem cells. PLoS ONE
  26. (2008). Effects of intracoronary autologous bone marrow cells on left ventricular function in acute myocardial infarction: a systematic review and meta-analysis for randomized controlled trials. Coron Artery Dis
  27. (2007). Generating neuron-like cells from BM-derived mesenchymal stromal cells in vitro. Cytotherapy
  28. (2006). Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet
  29. (2007). Granulocyte-colony-stimulating factor in acute myocardial infarction: future perspectives after FIRSTLINEAMI and REVIVAL-2. Nat Clin Pract Cardiovasc Med
  30. (2008). Hepatocyte growth factor combined with insulin like growth factor-1 improves expression of GATA-4 in mesenchymal stem cells cocultured with cardiomyocytes.
  31. (2012). High-efficiency matrix modulus-induced cardiac differentiation of human mesenchymal stem cells inside a thermosensitive hydrogel. Acta Biomater
  32. (2009). Human bone marrow stem cells co-cultured with neonatal rat cardiomyocytes display limited cardiomyogenic plasticity. Cytotherapy
  33. (2009). Human mesenchymal stromal cells from adult and neonatal sources: comparative analysis of their morphology, immunophenotype, differentiation patterns and neural protein expression. Cytotherapy
  34. (2007). Human placenta and bone marrow derived MSC cultured in serum-free, b-FGF-containing medium express cell surface frizzled-9 and SSEA-4 and give rise to multilineage differentiation. Differentiation
  35. (2011). Human term placenta-derived mesenchymal stromal cells are less prone to osteogenic differentiation than bone marrow-derived mesenchymal stromal cells. Stem Cells Dev
  36. (2005). Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells
  37. (2008). Imm unomodulatory effect of mesenchymal stromal cells: possible mechanisms. Regen Med
  38. (2008). Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells
  39. (2011). Immunohistochemical analysis of human mesenchymal stem cells differentiating into chondrogenic, osteogenic, and adipogenic lineages. Methods Mol Biol
  40. (2003). Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy
  41. (2006). Immunoregulatory function of mesenchymal stem cells.
  42. (2005). Increasing donor age adversely impacts beneficial effects of bone marrow but not smooth muscle myocardial cell therapy.
  43. (2007). Induction of neural-like differentiation in human mesenchymal stem cells derived from bone marrow, fat, spleen and thymus. Bone
  44. (2006). Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction.
  45. (2006). Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction.
  46. (2009). Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell
  47. (2008). Intravenous infusion of mesenchymal stem cells enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction. Basic Res Cardiol
  48. (2006). Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesissupportive function and other potentials. Haematologica
  49. (2009). Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. Histochem Cell Biol
  50. (2005). Isolation and Identification of a Multilineage Potential Mesenchymal Cell from Human Placenta. Placenta
  51. (2007). Left atrial volume: predictor of atrial fibrillation in patients with degenerative mitral regurgitation.
  52. (2003). Matrix cells from Wharton's jelly form neurons and glia. Stem Cells
  53. (2012). Mechanisms for progenitor cellmediated repair for ischemic heart injury. Curr Stem Cell Res Ther
  54. (2010). Mesenchymal stem cell therapy for treatment of cardiovascular disease: helping people sooner or later. Stem Cells Dev
  55. (2009). Mesenchymal stem cell: present challenges and prospective cellular cardiomyoplasty approaches for myocardial regeneration. Antioxid Redox Signal
  56. (2004). Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res
  57. (2006). Mesenchymal stem cells as trophic mediators.
  58. (2004). Mesenchymal stem cells in the Wharton's jelly of the human umbilical cord. Stem Cells
  59. (2011). Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res
  60. (2008). Method to isolate mesenchymal-like cells from Wharton's Jelly of umbilical cord. Methods Cell Biol
  61. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy
  62. (2004). Myogenic fusion of human bone marrow stromal cells, but not hematopoietic cells. Blood
  63. (2002). Neurogenic differentiation of murine and human adipose-derived stromal cells.
  64. (2010). New emerging potentials for human Wharton's jelly mesenchymal stem cells: immunological features and hepatocyte-like differentiative capacity. Stem Cells Dev
  65. (2012). Nuclear cardiac troponin and tropomyosin are expressed early in cardiac differentiation of rat mesenchymal stem cells. Differentiation
  66. (2010). Proteome analysis of human Wharton's jelly cells during in vitro expansion. Proteome Sci
  67. (2011). Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction.
  68. (2008). Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation. J Tissue Eng Regen Med
  69. (2012). Restricted myogenic potential of mesenchymal stromal cells isolated from umbilical cord. Cell Transplant
  70. (1992). Skeletal muscle blood flow abnormalities in rats with a chronic myocardial infarction: rest and exercise.
  71. (2006). Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA
  72. (2010). Stem cell therapy for myocardial infarction: are we missing time? Cardiology
  73. Stem cells in the umbilical cord.
  74. (2003). Stem cells: Fusion brings down barriers. Nature
  75. (2006). Stem-cell therapy after acute myocardial infarction: the focus should be on those at risk. Lancet
  76. (2008). Stem-cell therapy for cardiac disease.
  77. (2001). Surface protein characterization of human adipose tissue-derived stromal cells.
  78. (2008). Survival characteristics and prognostic variables of dogs with mitral regurgitation attributable to myxomatous valve disease.
  79. (2008). Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther
  80. (2008). TGF-beta induces the differentiation of bone marrow stem cells into immature cardiomyocytes. Biochem Biophys Res Commun
  81. (2011). The stimulation of the cardiac differentiation of mesenchymal stem cells in tissue constructs that mimic myocardium structure and biomechanics. Biomaterials
  82. (2007). Therapeutic potential of human umbilical cord derived stem cells in a rat myocardial infarction model. Ann Thorac Surg
  83. (2005). Time course of myocardial stromal cellderived factor 1 expression and beneficial effects of intravenously administered bone marrow stem cells in rats with experimental myocardial infarction. Basic Res Cardiol
  84. (2011). Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Rev
  85. (2008). Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells
  86. (2009). Why are MSCs therapeutic? New data: new insight.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.